Rani Therapeutics (RANI) News Today $1.40 +0.10 (+7.69%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Buy" from AnalystsShares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been given a consensus rating of "Buy" by the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buyDecember 20 at 4:51 AM | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Insider Buys $29,993.20 in StockDecember 17, 2024 | insidertrades.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Insider Kate Mckinley Acquires 17,960 SharesRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) insider Kate Mckinley purchased 17,960 shares of the company's stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $1.67 per share, for a total transaction of $29,993.20. Following the completion of the transaction, the insider now directly owns 17,960 shares of the company's stock, valued at $29,993.20. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.December 16, 2024 | marketbeat.comInsider Buying: Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) CEO Purchases 10,296 Shares of StockDecember 11, 2024 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Merus (MRUS), Trevi Therapeutics (TRVI) and Day One Biopharmaceuticals (DAWN)December 5, 2024 | markets.businessinsider.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Consensus Rating of "Buy" by AnalystsRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has earned an average rating of "Buy" from the seven brokerages that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the coNovember 25, 2024 | marketbeat.comWhat is Zacks Small Cap's Forecast for RANI FY2024 Earnings?Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - Analysts at Zacks Small Cap raised their FY2024 earnings per share estimates for shares of Rani Therapeutics in a research note issued to investors on Wednesday, November 20th. Zacks Small Cap analyst J. Vandermosten now expects thatNovember 25, 2024 | marketbeat.comRANI: Third Quarter UpdateNovember 21, 2024 | finance.yahoo.comRani Therapeutics Advances in Biotherapeutics MarketNovember 19, 2024 | markets.businessinsider.comRani Therapeutics Holdings: Buy Rating Backed by Strong Financial Outlook and Strategic Focus on RT-114 ProgramNovember 19, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Rani Therapeutics (NASDAQ:RANI)HC Wainwright restated a "buy" rating and issued a $9.00 price objective on shares of Rani Therapeutics in a research report on Tuesday.November 19, 2024 | marketbeat.comMaxim Group Remains a Buy on Rani Therapeutics Holdings (RANI)November 15, 2024 | markets.businessinsider.comRani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate UpdateNovember 14, 2024 | markets.businessinsider.comRani Therapeutics Holdings Inc Class A RANINovember 10, 2024 | morningstar.comRani Therapeutics Holdings options imply 12.6% move in share price post-earningsNovember 10, 2024 | markets.businessinsider.comRani Therapeutics to Participate in Upcoming Investor ConferencesNovember 8, 2024 | finance.yahoo.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Buy" by AnalystsShares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been given a consensus recommendation of "Buy" by the seven research firms that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and one has given a stOctober 31, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Sees Significant Growth in Short InterestRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 2,550,000 shares, a growth of 223.4% from the September 30th total of 788,600 shares. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is presently 1.7 days. Approximately 12.3% of the shares of the company are short sold.October 25, 2024 | marketbeat.comRANI: New Triagonist Data in Weight LossOctober 22, 2024 | msn.comRani Therapeutics: Innovative Oral Delivery System and Promising Obesity Treatment Potential Support Buy RatingOctober 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rani Therapeutics: Promising Developments in Oral Obesity Treatment with RaniPill™October 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rani Therapeutics: Promising Developments in Oral Obesity Treatment with RaniPill™October 19, 2024 | markets.businessinsider.comRani Therapeutics (NASDAQ:RANI) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Rani Therapeutics in a research note on Friday.October 18, 2024 | marketbeat.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder Sells $10,147,804.00 in StockOctober 18, 2024 | insidertrades.comRani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin TriagonistOctober 17, 2024 | markets.businessinsider.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Major Shareholder South Cone Investments Limited Sells 3,829,360 SharesRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) major shareholder South Cone Investments Limited sold 3,829,360 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $2.65, for a total value of $10,147,804.00. Following the completion of the sale, the insider now owns 8,302,194 shares of the company's stock, valued at $22,000,814.10. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.October 17, 2024 | marketbeat.com3 Penny Stocks to Watch Now, 10/15/24October 16, 2024 | msn.comWhy Rani Therapeutics Shares Are Down 23% TodayOctober 16, 2024 | benzinga.comRani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing WarrantsOctober 15, 2024 | globenewswire.comOppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy’ StocksOctober 12, 2024 | markets.businessinsider.comRani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 8, 2024 | globenewswire.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Buy" from BrokeragesRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has earned an average recommendation of "Buy" from the seven analysts that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buyOctober 6, 2024 | marketbeat.comRani Therapeutics Hldgs (NASDAQ:RANI) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comRani Therapeutics (NASDAQ:RANI) Shares Down 4.3% Rani Therapeutics (NASDAQ:RANI) Trading Down 4.3%October 3, 2024 | marketbeat.comRani Therapeutics to Participate in September Investor ConferencesSeptember 3, 2024 | globenewswire.comChemomab Therapeutics: Strong Buy Rating on Robust Financials and Positive Clinical Trial OutcomesAugust 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioCardia (BCDA) and CytomX Therapeutics (CTMX)August 22, 2024 | markets.businessinsider.comLykos to cut 75% of workforce, founder to exit board after drug setbackAugust 16, 2024 | msn.comHC Wainwright Lowers Rani Therapeutics (NASDAQ:RANI) Price Target to $9.00HC Wainwright dropped their target price on Rani Therapeutics from $13.00 to $9.00 and set a "buy" rating on the stock in a report on Friday.August 16, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)August 16, 2024 | markets.businessinsider.comFY2024 EPS Estimates for Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Reduced by AnalystRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) - Analysts at Cantor Fitzgerald reduced their FY2024 earnings per share (EPS) estimates for shares of Rani Therapeutics in a report released on Monday, August 12th. Cantor Fitzgerald analyst O. Brayer now anticipates that the company wiAugust 14, 2024 | marketbeat.comXLerator Network Selects 8 Life Science Startups Across Southeast for NIH-Funded Entrepreneurship Program: I-RED's Second Cohort AnnouncedAugust 14, 2024 | finance.yahoo.comRANI: Second Quarter ResultsAugust 12, 2024 | msn.comInnovative Oral Delivery Platform Drives Buy Rating for Rani Therapeutics HoldingsAugust 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Lumos Pharma (LUMO) and Rani Therapeutics Holdings (RANI)August 7, 2024 | markets.businessinsider.comRani Therapeutics (NASDAQ:RANI) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPSRani Therapeutics (NASDAQ:RANI - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.03.August 7, 2024 | marketbeat.comRani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate UpdateAugust 7, 2024 | finance.yahoo.comOppenheimer Initiates Coverage of Rani Therapeutics Holdings (RANI) with Outperform RecommendationAugust 3, 2024 | msn.comRani Therapeutics to Participate in August Investor ConferencesJuly 29, 2024 | globenewswire.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of "Buy" from AnalystsRani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has been assigned an average rating of "Buy" from the seven brokerages that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating toJuly 23, 2024 | marketbeat.com Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover RANI Media Mentions By Week RANI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RANI News Sentiment▼1.430.60▲Average Medical News Sentiment RANI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RANI Articles This Week▼42▲RANI Articles Average Week Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYRX News DSGN News PROC News BTMD News NGNE News VYGR News CTNM News SLRN News KMDA News TRVI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RANI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
